TABLE 2.
Effect of treatment with oseltamivir, ribavirin, and their combinations on the survival of mice inoculated with A/Turkey/15/06 (H5N1) influenza virus
| Oseltamivir dose (mg/kg/day) | Results obtained with the following ribavirin dose (mg/kg/day)a:
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0
|
37.5
|
55
|
75
|
|||||||||
| No. of survivors/total no. of mice (%) | Day of death (mean ± SD) | Hazard ratiob | No. of survivors/ total no. of mice (%) | Day of death (mean ± SD) | Hazard ratio | No. of survivors/total no. of mice (%) | Day of death (mean ± SD) | Hazard ratio | No. of survivors/total no. of mice (%) | Day of death (mean ± SD) | Hazard ratio | |
| 0 | 0/10 (0) | 9.7 ± 0.3 | 1 | 1/10 (10) | 10.4 ± 0.2 | 0.57 | 5/10 (50)* | 10.6 ± 0.2 | 0.18** | 5/10 (50)** | 12.2 ± 0.4* | 0.15** |
| 10 | 2/10 (20) | 10.7 ± 0.6 | 0.47 | 5/10 (50)*,† | 11.4 ± 0.3* | 0.16**,† | 5/10 (50)** | 11.0 ± 0.0*,° | 0.15**,° | 3/10 (30)* | 10.8 ± 0.1† | 0.28* |
| 50 | 3/10 (30) | 11.7 ± 0.8* | 0.27* | 5/10 (50)** | 12.5 ± 0.7*,†† | 0.16**,† | 7/10 (70)**,° | 13.8 ± 0.2*,°°,†† | 0.07** | 7/10 (70)**,° | 15.3 ± 0.6*,°°,†† | 0.07** |
| 100 | 9/10 (90)** | 15 | 0.02** | 9/10 (90)**,†† | 10 | 0.02**,†† | 7/10 (70)** | 11.7 ± 0.3*,°° | 0.08** | 8/10 (80)** | 14.0 ± 0.0*,†† | 0.05** |
Boldface type indicates a higher percentage of survivors, a longer time to death, or a lower risk of death compared with the values obtained when either compound was used alone. *, P < 0.01 compared with the results for the placebo-treated control group; **, P < 0.001 compared with the results for the placebo-treated control group; °, P < 0.05, compared with the results for the group treated with oseltamivir alone; °°, P < 0.01 compared with the results for the group treated with oseltamivir alone; †, P < 0.05 compared with the results for the group treated with ribavirin alone; ††, P < 0.01 compared with the results for the group treated with ribavirin alone.
An estimate of the relative risk of death.